No Data
No Data
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Akebia Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $6
Akebia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 200.11% HC Wainwright & Co. $5 → $6 Maintains Buy 03/15/2024 150.09% HC Wainwright & Co. → $5 R
Sector Update: Health Care Stocks Advance Premarket Thursday
Health care stocks were advancing premarket Thursday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently 0.5% higher. Akebia Therapeutics (AKBA
Sector Update: Health Care
Health care stocks were mixed premarket Thursday with the Health Care Select Sector SPDR Fund (XLV) inactive and iShares Biotechnology ETF (IBB) recently up 0.5%. Akebia Therapeutics (AKBA) shares wer
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved
loading...
No Data
70108039 : good pick me up 2.5 ok deal